STAT+: A patent win for Pfizer and BridgeBio

STAT PlusNewsletterThe Readout A patent win for Pfizer and BridgeBio A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine ChenApril 29, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Several biotech leaders were named in this list of the most influential Bostonians. Is there anyone you think should have made the list who didn’t? Let me know your thoughts.Advertisement The need-to-know this morning The Italian pharma company Chiesi is buying KalVista Therapeutics for $1.9 billion, adding an approved treatment for a genetic swelling disorder to its rare-disease portfolio. The deal values KalVista at $27 per share, or a 40% premium to its Tuesday closing stock price. The KalVista medicine, called Ekterly, is a pill used to treat acute swelling attacks in people with hereditary angioedema. Biogen, AstraZeneca, Regeneron Pharma, Abbvie and GSK reported first-quarter earnings. FDA plans to review AZ, Amgen trials in real time In an effort to get drugs on the market faster, the FDA announced yesterday it will start reviewing trial data in real time, starting with oncology studies conducted by AstraZeneca and Amgen. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech April 28, 2026 STAT Plus: FDA launches effort to speed up clinical trials, using AI Biotech April 28, 2026 Fauci adviser David Morens indicted on charges of concealing emails, avoiding records requests Advertisement The Readout April 28, 2026 STAT Plus: Boehringer’s obesity drug shows 16.6% weight loss; more data needed Pharma April 28, 2026 STAT Plus: Eli Lilly enlists AI startup for next-generation gene editors Biotech April 27, 2026 STAT Plus: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy Subscriber Picks